Life (Basel) 2021 Jun 16;11(6):565.
Statins in COVID-19 Therapy
Justyna Olszewska-Parasiewicz 1, Łukasz Szarpak 2 3, Sylwester Rogula 4, Aleksandra Gąsecka 4, Urszula Szymańska 1, Maria Kwiatkowska 1, Milosz J Jaguszewski 5, Radosław Sierpiński 6, Artur Zaczyński 1, Waldemar Wierzba 1 7, Dariusz A Kosior 1 8
Inhibitors of 3-hydroxy-3methylgultaryl-coenzyme A reductase (statins) are one of the main groups of drugs used in preventing and treating cardiovascular diseases worldwide. They are widely available, cheap, and well-tolerated. Based on statins’ pleiotropic properties, including improvement of endothelial dysfunction, antioxidant properties, atherosclerotic plaque stabilization, and inhibition of inflammatory responses, it can be hypothesized that the use of statins, at least as an adjuvant in antiviral therapy, may be justified. All these effects might be especially beneficial in patients with COVID-19, suffering from endothelial dysfunction, microvascular and macrovascular thrombosis, and cytokine storm. Here, we review the recent data regarding the pathophysiology of SARS-CoV-2 activity in host cells, proposed COVID-19 therapy, the pleiotropic activity of statins, and statins in clinical trials in respiratory infections. According to the guidelines of the European and American Cardiac Societies, in patients with cardiovascular disease or high cardiovascular risk with concomitant COVID-19 it is recommended to continue statin treatment. However, the initiation of statin therapy de novo in COVID-19 treatment should only be done as part of a clinical trial.
Keywords: COVID-19; SARS-CoV-2; pleiotropic effects; statins; therapy.